Abstract | BACKGROUND: METHODS: We assessed the clinical outcomes of 8711 patients in 13 trials receiving anti-PD-1/PD-L1-based therapy or non- immunotherapy as first-line treatment, and different predictors were investigated. RESULTS: Overall, compared with non- immunotherapy, anti-PD-1/PD-L1-based therapy reduced the risk of death by 31% (HR 0.69, 95%CI: 0.60-0.79) for all cancers. Stratified analysis showed that the progression-free survival (PFS) benefit from anti-PD-1/PD-L1-based therapy existed in all three PD-L1 status subgroups (tumour proportion score, TPS ≥50%: HR 0.54, 95%CI: 0.38-0.78; TPS 1-49%: HR 0.56, 95%CI: 0.46-0.68; TPS <1%: HR 0.82, 95%CI: 0.73-0.91; interaction, p < 0.01). ICI therapy also prolonged PFS in males (HR 0.64, 95%CI: 0.50-0.83) and younger patients (HR 0.70, 95%CI: 0.52-0.93), and they might prolong overall survival (OS) in patients without brain metastasis (HR 0.54, 95%CI: 0.41-0.71). CONCLUSION: PD-L1 expression level alone is imperfect to predict the efficacy of anti-PD-1/PD-L1-based therapies as first-line cancer treatment. Meanwhile, sex, age, and status of brain metastases might also be predictive parameters for the selection of cancer patients.
|
Authors | Yaojie Zhou, Chengdi Wang, Yuting Jiang, Pengwei Ren, Jun Shao, Paierhati Tuersun, Weimin Li |
Journal | Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
(Biomarkers)
Vol. 25
Issue 6
Pg. 441-448
(Sep 2020)
ISSN: 1366-5804 [Electronic] England |
PMID | 32744106
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- B7-H1 Antigen
- Biomarkers, Tumor
- CD274 protein, human
- Immune Checkpoint Inhibitors
- PDCD1 protein, human
- Programmed Cell Death 1 Receptor
- atezolizumab
|
Topics |
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- B7-H1 Antigen
(genetics)
- Biomarkers, Tumor
(genetics)
- Female
- Gene Expression Regulation, Neoplastic
(drug effects, immunology)
- Humans
- Immune Checkpoint Inhibitors
(therapeutic use)
- Immunotherapy
(adverse effects)
- Male
- Middle Aged
- Neoplasms
(blood, genetics, immunology, therapy)
- Programmed Cell Death 1 Receptor
(genetics)
- Progression-Free Survival
- Treatment Outcome
|